Skip to main content
Figure 5 | Journal of Neuroinflammation

Figure 5

From: A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model

Figure 5

Compound 069A suppresses proinflammatory cytokine up-regulation in AD mouse model. A schematic of the experimental paradigm is shown. Treatment with 069A resulted in significant suppression of the Aβ-induced increase in the hippocampal levels of the proinflammatory cytokines IL-1β (A), TNFα (B) and S100B (C). Mice were infused ICV with either the diluent control (C) or the injurious oligomeric form of human Aβ1–42 (I) for 4 weeks. Starting at 3 weeks after the start of Aβ infusion, mice were administered by daily oral gavage either 069A (2.5 mg/kg; I + Cmpd) or vehicle (I + Veh) for two weeks. Spontaneous alternation of mice was measured for 10 days in the Y-maze, a hippocampus-dependent spatial learning task, beginning at day 50 after the start of Aβ infusion. Mice were sacrificed on day 60, and hippocampal extracts analyzed by ELISA. Data are means ± SEM of n = 5 mice per group. Significantly different from Aβ-injured: *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page